|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Quark Pharmaceuticals |
|---|---|
| Information provided by: | Quark Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00683553 |
Purpose
This is a Phase 1, randomized, double-blind, dose escalation, safety and pharmacokinetic study. The study will be conducted in approximately 10 sites in the United States. Up to 48 patients at high risk for AKI (CCF score ≥ 5 OR an estimated GFR (eGFR) <60 mL/min/1.73 m2) who have undergone major cardiovascular surgery will participate. Patients will receive a single IV injection of I5NP or placebo following cardiovascular surgery. I5NP will be administered 4 hours (+/- 30 minutes) following removal of the cardiopulmonary bypass machine (CBM).
The duration of the study is approximately 44 days, inclusive of a 14 day screening period. Patients will be contacted by phone at 6 and 12 months for follow-up questions. Patient visits are screening, day of surgery, hospital in-patient Days 1, 2, 3 - 5 and Day 7 or hospital discharge. Safety follow-up will continue until 30 days post-surgery. 2 phone calls will be made at 6 and 12 months after date of surgery.
| Condition | Intervention | Phase |
|---|---|---|
|
Acute Renal Failure Acute Kidney Injury |
Drug: I5NP Drug: Placebo |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients at High Risk of Acute Kidney Injury Undergoing Major Cardiovascular Surgery |
| Enrollment: | 3 |
| Study Start Date: | May 2008 |
| Study Completion Date: | September 2010 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: I5NP drug |
Drug: I5NP
Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
Other Name: QPI-1002
|
| Placebo Comparator: Placebo |
Drug: I5NP
Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
Other Name: QPI-1002
Drug: Placebo
Single IV injection of saline
|
The drug (I5NP) is a small interfering RNA that is being developed to protect patients from acute kidney injury after cardiac bypass surgery. This study will test the safety of I5NP and measure how long the drug stays in the blood stream after injection. This study is not meant to test if I5NP protects kidneys from the damage that may occur in rare cases during surgery. Another purpose of this dose escalation study is to find out the right dose of the experimental drug to be given to study subjects in future studies. Even though there were no harmful effects seen in the animals tested, we do not know what side effects the experimental drug might cause in humans.
Eligibility| Ages Eligible for Study: | 21 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria (before surgery):
Inclusion Criteria (during surgery):
Inclusion Criteria (after surgery):
Exclusion Criteria (before surgery):
Patient has had cancer or may be predisposed due to a family history of:
Women of childbearing potential are to be excluded from this study. Every female subject is considered of childbearing potential unless she has had sterilization surgery, or is post-menopausal.
Exclusion Criteria (during surgery):
Exclusion Criteria (after surgery):
Contacts and Locations| United States, Alabama | |
| University of Alabama at Birmingham | |
| Birmingham, Alabama, United States, 35233 | |
| United States, Arizona | |
| Mayo Clinic Hospital | |
| Phoenix, Arizona, United States, 85054 | |
| United States, District of Columbia | |
| George Washington University | |
| Washington, District of Columbia, United States, 20037 | |
| United States, Missouri | |
| Washington University | |
| St. Louis, Missouri, United States, 63110 | |
| United States, Ohio | |
| Cleveland Clinic Foundation | |
| Cleveland, Ohio, United States, 44195 | |
| United States, Pennsylvania | |
| University of Pittsburgh Medical Center | |
| Pittsburgh, Pennsylvania, United States, 15213 | |
| United States, Texas | |
| Texas Heart Institute | |
| Houston, Texas, United States, 77030 | |
| The Methodist Hospital | |
| Houston, Texas, United States, 77030 | |
| University of Texas | |
| Houston, Texas, United States, 77030 | |
| United States, Virginia | |
| University of Virginia School of Medicine | |
| Charlottesville, Virginia, United States, 22908-0688 | |
| Study Director: | Martin S. Polinsky, M.D. | Quark Pharmaceuticals |
More Information
| Responsible Party: | Mike Johnston, Director, Regulatory Affairs, Quark Pharmaceuticals, Inc. |
| ClinicalTrials.gov Identifier: | NCT00683553 History of Changes |
| Other Study ID Numbers: | QRK.004 |
| Study First Received: | May 21, 2008 |
| Last Updated: | November 12, 2010 |
| Health Authority: | United States: Food and Drug Administration |
|
Acute Renal Failure Acute Kidney Injury |
|
Acute Kidney Injury Renal Insufficiency Kidney Diseases Urologic Diseases |